Literature: Bone Pain Palliation
Wieder HA, Lassmann M, Allen-Auerbach MS, Czernin J, Herrmann K.
Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters.
World J Radiol. 2014 Jul 28;6(7):480-5.
Nilsson S.
Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Am Soc Clin Oncol Educ Book. 2014:e132-9.
Shirley M, McCormack PL.
Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
Drugs. 2014 Apr;74(5):579-86.
Dauer LT, Williamson MJ, Humm J, O'Donoghue J, Ghani R, Awadallah R, Carrasquillo J, Pandit-Taskar N, Aksnes AK, Biggin C, Reinton V, Morris M, St Germain J.
Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer.
Health Phys. 2014 Apr;106(4):494-504.
Pandit-Taskar N, Larson SM, Carrasquillo JA.
Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.
J Nucl Med. 2014 Feb;55(2):268-74.
Wissing MD, van Leeuwen FW, van der Pluijm G, Gelderblom H.
Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.
Clin Cancer Res. 2013 Nov 1;19(21):5822-7.
Joung JY, Ha YS, Kim IY.
Radium Ra 223 dichloride in castration-resistant prostate cancer.
Drugs Today (Barc). 2013 Aug;49(8):483-90.
Correa-González L, Arteaga de Murphy C, Pichardo-Romero P, Pedraza-López M, Moreno-García C, Correa-Hernández L.
(153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies.
Arch Med Res. 2014 May;45(4):301-8.
Sabet A, Khalaf F, Mahjoob S, Al-Zreiqat A, Biersack HJ, Ezziddin S.
May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.
Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):80-8. eCollection 2013.
Ponsard B, Srivastava SC, Mausner LF, Russ Knapp FF, Garland MA, Mirzadeh S.
Production of Sn-117m in the BR2 high-flux reactor.
Appl Radiat Isot. 2009 Jul-Aug;67(7-8):1158-61.
Oyen WJ, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M, Brans B.
Targeted therapy in nuclear medicine--current status and future prospects.
Ann Oncol. 2007 Nov;18(11):1782-92.
Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJ, Tennvall J.
Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".
Eur J Nucl Med Mol Imaging. 2007 May;34(5):772-86.